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Background:  Australia  commenced  a publically-funded,  National  Human  Papillomavirus  (HPV)  Vaccina-
tion Program  in 2007 with  a two  year  catch-up  phase  for females  aged  12–26  years.
Objective:  To  identify  the factors  associated  with  the  uptake  of the  HPV  vaccine  (which  has  a  recommended
3-dose  schedule  in  Australia)  by  young  adult  women  vaccinated  by  general  practitioners  and  community-
based  programs  within  the  catch-up  phase.
Methods:  1139  women  who  were  eligible  to receive  the free  HPV  vaccine  during  the  catch-up  period
were  recruited  in 2008–2009  (age  20–29  years  at recruitment),  in New  South  Wales,  after  having  a
normal  (negative)  cervical  smear  result  recorded  on the  NSW  Pap  Test  Register.  Participants  completed
a  self-administered  questionnaire  providing  information  on vaccination  status,  and  sociodemographic
and  other  factors.
Results: Overall,  880  (77%)  women  reported  receiving  ≥1  dose  of  the vaccine  and 777 women  (68%)
reported  receiving  ≥2 doses.  In  multivariable  analysis  (adjusting  for the  period  for  which  each  woman
was  eligible  for free  HPV  vaccination),  uptake of ≥1  dose  of the  vaccine  was  signiﬁcantly  associated
with  being  born  in Australia  (p < 0.01),  being  single  (p  = 0.02),  being  nulliparous  (p  <  0.01),  living in  a
higher  socioeconomic  status  area  (p-trend  = 0.03),  living  in  more  remote  areas  (p  = 0.03),  drinking  alcohol
(p <  0.01)  and  using  hormonal  contraceptives  (p <  0.01).  Although  vaccinated  women  were  more  likely
to  have  fewer  sexual  partners  than unvaccinated  women  (p-trend  = 0.02),  they were also  more  likely  to
report  a  prior  sexually  transmitted  infection  (STI)  (p  = 0.03).  Similar  factors  were  associated  with  receiving
≥2  doses.
Conclusions:  In this  group,  women  living  in  higher  socioeconomic  status  areas  were  more  likely  to  be vac-
cinated  against  HPV  in the catch-up  phase  of the national  program.  Although  vaccinated  women  tended
to  have  fewer  sexual  partners,  they  also  reported  prior  STIs,  which  may  be a marker  of  increased  risk of
prior  exposure  to HPV.  The  ﬁndings  of  this  study  reinforce  the  continuing  need  to  prioritise  equitable
delivery  of  vaccination  to various  population  subgroups.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-NDAbbreviations: GP, general practitioner; PTR, Pap Test Register; SES, socioeco-
omic status; STI, sexually transmitted infections.
∗ Corresponding author at: Lowy Cancer Research Centre, Prince of Wales Clinical
chool, University of New South Wales, Sydney 2052, NSW, Australia.
el.: +61 2 9385 3817.
E-mail address: k.canfell@unsw.edu.au (K. Canfell).
ttp://dx.doi.org/10.1016/j.vaccine.2015.01.024
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Australia was  one of the ﬁrst countries to implement a national
publically-funded human papillomavirus (HPV) vaccination pro-
gram. The program has involved the recommended administration
over 6 months of 3 doses of Gardasil quadrivalent vaccine (bioCSL
Australia/Merck Inc. Whitehouse Station, NJ, USA), which protects
against infection with the oncogenic HPV types 16 and 18, as well
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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s infection with types 6 and 11, which are implicated in the
evelopment of anogenital warts. School-based routine vaccina-
ion of 12–13 year old girls commenced in April 2007, and a school
nd general practitioner (GP)-based catch-up program involved
ffering free vaccination to females aged 12–26 years. Vaccina-
ion for women who had ﬁnished school was carried out by GP
ractices and community-based programs from July 2007 until
ecember 2009. In 2013, the program was also extended to 12–13
ear old boys, with a two-year catch-up in males to 14–15 years.
he catch-up provides the opportunity for older individuals to be
accinated, although population-level effectiveness in older age
ohorts is expected to be lower if more individuals have been pre-
iously exposed to vaccine-included HPV types. Vaccination status
s recorded at an individual level on the National HPV Vaccination
rogram Register (NHVPR) in Australia. The national coverage rates
ecorded on the NHVPR for those aged 18–26 years in 2007 were
5% for ≥1 dose and 32% for 3 doses (using 2007 population data
s the denominator) [1]. However, a 2011 survey of women in this
ge cohort (22–30 years in 2011) suggested under-notiﬁcation of
accine doses to the National HPV Vaccination Program Register
y providers, with 64% of surveyed women reporting ≥1 and 53%
eporting receiving 3 doses [1].
It is plausible that a number of socio-demographic factors may
ave been associated with vaccine uptake even within the free pub-
ic program. The population of women who were vaccinated in the
atch-up phase has yet to be fully characterised in terms of their
emographic proﬁles, sexual behaviour and lifestyle characteris-
ics; however a prior survey has identiﬁed that vaccinated young
dult women were more likely to be Australian born, a perma-
ent resident in 2007, English speaking at home, and unmarried
1]. There are also indications that adolescent and young women’s
egree of knowledge towards vaccination and the availability of
ree vaccination during the catch-up period was limited or vari-
ble [2,3]. It is also pertinent to assess vaccine uptake in relation
o behavioural factors relevant to the risk of prior HPV exposure
including the number of sexual partners and related measures),
ecause these have the potential to alter the overall effectiveness
f vaccination in the population. In clinical trials, prophylactic vac-
ination with quadrivalent vaccine was 98% effective in preventing
ervical high grade precancerous disease (CIN2/3), adenocarcinoma
n situ or cervical cancer related to HPV 16 and 18 in 16–26 year
ld women previously naive for these vaccine-included types, but
4% effective in prevention of this outcome in the trial population
verall (and 17% effective in prevention of all cervical high grade
esions regardless of causal HPV type) [4]. Women  reporting more
han four prior sexual partners were excluded [4], and so the over-
ll effectiveness of the vaccine in “real world” catch-up programs
as the potential to be lower than reported in the trial.
Taking into account the above issues, the objectives of the cur-
ent study were to assess whether socio-demographic, clinical
nd/or behavioural factors were associated with vaccine uptake in
 population of women who were 20–29 years old in 2008–2009,
nd were eligible to receive free vaccine at the time of the delivery
f catch-up HPV vaccination in Australia.
. Methods
.1. Study population and recruitment
This cross-sectional analysis was performed in a group of
omen who recently had a cervical screening test with a nor-
al  (negative) cytology result and were eligible for vaccination in
he catch-up phase. These women were recruited as controls for
 case-control study of the role of exogenous hormonal co-factors
n the development of cervical precancerous lesions (the “Cervical (2015) 2387–2394
Health Study”). Recruitment for the Cervical Health Study was  per-
formed in women  aged 20–64 years via invitation letters sent from
the centralised Pap Test Register (PTR) in New South Wales (NSW).
Recruitment of 20–29 year old subjects began in March 2008. Cases
for the Cervical Health Study were recruited as women  on the
PTR with a record of a low or high grade cytological or histolog-
ical abnormality. Controls matched to cases by age and local area
were recruited from the PTR with a record of a normal cytological
result in the same week as the abnormal smear for the matched
case. All participants gave informed consent before taking part.
Exclusion criteria included hysterectomy, current pregnancy, mor-
bidity or impairment preventing participation and prior treatment
for a cervical abnormality in the three months prior to recruit-
ment. Complete history of cervical cytology and histology dates
and results from the PTR were obtained for all participants. The
current analysis was  restricted to participants recruited between
March 2008 and November 2009, who  had returned a completed
questionnaire by 1 January 2010 and on the date of completing the
questionnaire had been eligible for the free vaccination catch-up
program for at least one day (i.e. those aged ≤26 years on 1 July
2007 and thus ≤29 years of age at the time of recruitment). The
time for which individual women had been eligible for vaccination
was taken into account in the analysis.
Ethical approval for the release of PTR data was  originally
obtained in 2006 (Ref 2004/05/073) from the Human Research
Ethics Committee of the Cancer Institute NSW. Following the
implementation of the National HPV Vaccination Program, a pro-
tocol amendment to collect information on HPV vaccination status
through the study questionnaire was approved in 2007, under the
same reference number, by the NSW Population and Health Ser-
vices Research Ethics committee.
Participants were sent a detailed self-administered question-
naire which requested demographic, lifestyle and medical details
as well as reproductive and sexual history. Women  were asked
to indicate whether they had ever been vaccinated against HPV
(additionally described on the questionnaire as “vaccinated against
cervical cancer”), the year of vaccination and the number of doses
received. Because study recruitment was  ongoing during the catch-
up program (rather than being performed after its completion), the
reported number of doses at the time of questionnaire comple-
tion did not necessarily reﬂect the ﬁnal number of doses received.
Therefore, for the current analysis the factors inﬂuencing 3-dose
uptake could not be directly assessed. In order to increase statisti-
cal power, we analysed factors associated with uptake of ≥1 doses
of vaccine. We  also performed a secondary analysis on factors asso-
ciated with receiving two  or more doses. The time for which the
vaccine was  available free of charge for each participant was  taken
into account in the analysis.
2.2. Socio-demographic factors
Socio-demographic factors that were assessed included age at
questionnaire completion; the highest educational qualiﬁcation
completed; marital status, country of birth; and the number of full
term pregnancies. We  also used the Socio-Economic Indexes for
Areas (SEIFA) [5] quintiles [1 = lowest socioeconomic status (SES)
to 5 = highest] and the Accessibility-Remoteness Index of Australia
Plus (ARIA+) [6], which is a standard Australian Bureau of Statistics-
endorsed measure of geographical remoteness.
2.3. Clinical and behavioural characteristicsClinical characteristics that were assessed were: the number
of cytological smear tests prior to the year of vaccination in
vaccinated participants or prior to the normal index cytological
test in unvaccinated women, the number of previous high grade
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Table  1
Year of ﬁrst dose of HPV vaccine by number of doses received for women  aged 20–29 years at study recruitment (2008–2009), in NSW, Australia (self-reported vaccination
uptake).
Year of ﬁrst dose Number of doses received, n (row %)
One Two  Three Total n
77(40%) 64(33%) 53(27%) 194
18(3%) 74(14%) 433(82%) 525
8(5%) 6(4%) 147(91%) 161
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n=1925 controls eligible for the federal government free “catch-up”
vaccination program for at least one day (i.e. those aged 26 and under 
on the 1st July 2007) were invited between March 2008 and 
November 2009 to participate in the Cervical Health Study. 
n=1222 (64% of the group above) consented and returned a completed 
questionnaire by 1st January 2010 
n=1139 (93% of the group directly above) had non-missing, valid 
information on vaccination and potential determinants. 
Only these subjects were included in the analyses for this paper. 
703 women 
declined
participation 
83 excluded due 
to missing dataSame calendar year as questionnaire response 
One  calendar year before questionnaire response
Two  calendar years before questionnaire response 
ytological and histological lesions and low grade lesions, and
he number of detected precancerous lesions overall. Behavioural
haracteristics that were assessed included history of any sexu-
lly transmitted infection (STI), lifetime number of sexual partners,
lcohol consumption, use of tobacco and use of hormonal contra-
eptives.
.4. Statistical methods
Multivariable logistic regression modelling was  used to iden-
ify the factors associated with vaccination status. Independent
ariables included all socio-demographic, clinical and behavioural
actors described previously, with the exception of the variables
epresenting the numbers of prior low grade and high grade lesions.
hese variables were excluded from the full model because of their
ollinear relationship with the variable representing prior number
f total lesions (i.e. high grade and low grade combined). Esti-
ated coefﬁcients for the excluded variables were obtained by
tting a separate full model that excluded prior number of total
esions. A reduced multivariable logistic regression model was  then
btained by sequential exclusion of statistically non-signiﬁcant
actors (in decreasing order of p-values) that were not observed
onfounders of other effects (using a 10% change-in-estimate crite-
ion for confounding). However, since the reduced model provided
o appreciable reduction in the standard errors of effect estimates,
nly the results of the full multivariable analysis are reported here.
inear trend tests were performed by sequentially substituting the
inary indicator variables of inherently ordinal determinants with
heir ordinal counterparts into the full logistic regression model.
he ordinal values for each level of each factor was taken to be
he median value of the data for that level for interval data or
onsecutive integers for ordered categories.
A complete case approach was adopted for all analyses, thus par-
icipants with missing/unknown information on vaccination status
nd/or any one of the factors of interest were excluded from all anal-
ses. The exception to this rule was the inclusion of the category
prefer not to answer” for lifetime number of sexual partners since
his was offered as a legitimate response option on the question-
aire. We  analysed factors associated with vaccine uptake of ≥1
oses in women with normal cervical smears. We  also performed
 secondary analysis on factors associated with receiving two or
ore doses of vaccine. All analyses were performed using Stata
1.0 software (StataCorp, College Station, TX, USA).
. Results
A total of 1925 controls were invited to participate in the Cer-
ical Health Study between March 2008 and November 2009 who
ere eligible for the catch-up vaccination program for at least one
ay (Fig. 1). Of these, 1222 (64%) consented to participate in the
ervical Health Study and returned a completed questionnaire by
 January 2010. A total of 7% (n = 83) of those who  consented to par-
icipate had missing or non-valid data on HPV vaccination and/or
t least one potential factor related to vaccination. These partici-
ants were excluded from all further analyses thus providing an
verall participation rate of ∼59%. All analyses were performed onFig. 1. Flowchart showing overall study recruitment process and subjects included
in the current analysis.
the remaining 1139 women. Of these, 880 (77%) reported receiv-
ing ≥1 doses and 777 (68%) women  reported receiving ≥2  doses
of vaccine. The timing of the reported number of doses in relation
to study recruitment is shown in Table 1. Women who received
fewer than 3 doses of vaccine and who  were vaccinated in the
same year as recruitment, or the year immediately before recruit-
ment, could still potentially complete the remainder of their doses
within the recommended time frame after completing the study
questionnaire (hence these women cannot contribute to an esti-
mate of actual dose completion rates in the study group). However,
an estimate of the vaccination completion rate was obtained for
those women  who  reported receiving their ﬁrst dose of vaccine 2
years before recruitment; amongst this subgroup of women, 91%
reported receiving all 3 doses of vaccine.
As expected, women were less likely to report being vaccinated
as the time for which they had been eligible for free vaccina-
tion decreased (Table 2). Table 2 also presents the odds ratios
for socio-demographic characteristics potentially associated with
vaccination uptake (≥1 dose). Women  who were single (never
married) had higher odds of being vaccinated compared to mar-
ried/partnered women. Women  with children were signiﬁcantly
less likely to be vaccinated than nulliparous women and those born
overseas were less likely to report being vaccinated than women
born in Australia. In addition, although there was  no signiﬁcant
association between educational attainment and vaccination sta-
tus, the likelihood of reporting being vaccinated decreased with
decreasing socio-economic status of the place of residence. The
adjusted odds of women  living in areas in the second lowest and
lowest socio-economic quintiles being vaccinated were around half
those of women living in areas in the highest quintile. Women  in
outer regional/remote/very remote areas were more likely to report
being vaccinated.
Table 3 presents clinical and behavioural characteristics by
vaccination status. Women  reporting a higher number of sexual
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Table  2
Socio-demographic characteristics by self-reported HPV vaccination status, based on ≥1 doses, in women  aged 20–29 years at study recruitment (2008–2009) in NSW,
Australia.
Characteristic Unvaccinated
n = 259 (23%)
Vaccinated
n = 880 (77%)
Unadjusted OR
(95%CI)
Adjusted OR
(95%CI)
Overall p-value
and p-trend , *
Age
20–21 30 (17%) 148 (83%) Ref. Ref.
22  25 (16%) 135 (84%) 1.09
(0.61–1.95)
1.33
(0.69–2.53)
23  28 (21%) 103 (79%) 0.75
(0.42–1.32)
0.79
(0.41–1.51)
0.59
24  31 (17%) 147 (83%) 0.96
(0.55–1.67)
1.36
(0.72–2.59)
0.73
25  30 (21%) 114 (79%) 0.77
(0.44–1.35)
1.39 (0.7–2.73)
26  41 (27%) 111 (73%) 0.55
(0.32–0.93)
0.94
(0.49–1.81)
27  48 (36%) 86 (64%) 0.36
(0.21–0.62)
1.18
(0.58–2.38)
28–29 26 (42%) 36 (58%) 0.28
(0.15–0.53)
1.35 (0.5–3.32)
Time  vaccine was  available free of charge to woman
24+ to 30 months 16 (13%) 105 (87%) Ref. Ref.
18+  to 24 months 67 (20%) 274 (80%) 0.62
(0.35–1.12)
0.61
(0.32–1.16)
<0.01
12+ to 18 months 66 (22%) 236 (78%) 0.54 (0.3–0.99) 0.51
(0.27–0.98)
<0.01
6+  to 12 months 73 (24%) 235 (76%) 0.49
(0.27–0.88)
0.44
(0.23–0.85)
1  day to 6 months 37 (55%) 30 (45%) 0.12
(0.06–0.25)
0.12
(0.05–0.31)
Highest qualiﬁcation completed
University degree or higher 101 (22%) 356 (78%) Ref. Ref.
Certiﬁcate/diploma 67 (23%) 221 (77%) 0.94 (0.6–1.33) 1.07
(0.69–1.64)
0.84
Trade/apprenticeship 8 (19%) 35 (81%) 1.24
(0.56–2.76)
1.50 (0.5–3.83) n/a
HSC  or leaving certiﬁcate 52 (20%) 204 (80%) 1.11
(0.76–1.62)
1.22
(0.76–1.96)
School certiﬁcate or less 31 (33%) 64 (67%) 0.59
(0.36–0.95)
0.97 (0.5–1.85)
SEIFA quintile
5—Highest SES 106 (20%) 422 (80%) Ref. Ref.
4  57 (23%) 194 (77%) 0.85
(0.59–1.23)
0.94
(0.59–1.50)
0.17
3 56 (25%) 167 (75%) 0.75
(0.52–1.08)
0.83
(0.51–1.35)
0.03
2  28 (32%) 60 (68%) 0.54
(0.33–0.88)
0.46
(0.23–0.91)
1—Lowest SES 12 (24%) 37 (76%) 0.77
(0.39–1.54)
0.56
(0.25–1.26)
ARIA plus
Major City 174 (22%) 630 (78%) Ref. Ref.
Inner Regional 68 (29%) 170 (71%) 0.69
(0.50–0.96)
0.68
(0.45–1.04)
0.03
Outer regional/remote/very remote 17 (18%) 80 (82%) 1.30
(0.75–2.25)
1.62
(0.83–3.18)
n/a
Marital status
Married or partnered 181 (29%) 445 (71%) Ref. Ref.
Single—never married 74 (15%) 419 (85%) 2.30
(1.70–3.11)
1.58
(1.09–2.27)
0.02
Single- divorced, separated or 4 (20%) 16 (80%) 1.63
(0.54–4.93)
2.7 (0.79–9.22) n/a
Widowed
Country of birth
Australia 195 (20%) 782 (80%) Ref. Ref.
Overseas-English speaking country 28 (37%) 48 (63%) 0.43
(0.26–0.70)
0.43
(0.24–0.76)
<0.01
Overseas-non English speaking country 36 (42%) 50 (58%) 0.35
(0.22–0.55)
0.31
(0.18–0.54)
n/a
Number of births
None 160 (18%) 740 (82%) Ref. Ref.
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Table  2 (Continued)
Characteristic Unvaccinated
n = 259 (23%)
Vaccinated
n = 880 (77%)
Unadjusted OR
(95%CI)
Adjusted OR
(95%CI)
Overall p-value
and p-trend , *
One 53 (37%) 90 (63%) 0.37
(0.25–0.54)
0.53
(0.32–0.88)
<0.01
Two or more 46 (48%) 50 (52%) 0.24
(0.15–0.36)
0.38
(0.21–0.66)
<0.01
ARIA plus: Accessibility-Remoteness Index of Australia Plus; HSC: higher school certiﬁcate; n/a: not applicable; SEIFA: Socio-Economic Indexes for Areas; SES: socioeconomic
status.
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able 3).
* P-values are from the multivariable model.
artners were less likely to report being vaccinated. However,
omen who reported having a prior STI (other than oncogenic
PV infection) had higher odds of reporting being vaccinated com-
ared to women who did not report a prior history of STIs. Reported
ptake of ≥1 dose of the vaccine was also associated with drink-
ng alcohol, with women who drank more likely to report being
accinated. In addition, past- and never-users of hormonal contra-
eptives had close to half the odds of being vaccinated than those of
urrent users. No signiﬁcant associations with vaccination uptake
ere observed for the number of prior cervical cytology tests (Pap
mears) or abnormal cytology tests.
These socio-demographic, clinical and behavioural characteris-
ics were also evaluated for their association with uptake of ≥2
oses versus no dose, and results were found to be similar to those
or ≥1 doses (detailed results not shown).
. Discussion
To our knowledge this is the ﬁrst study to investigate a com-
rehensive range of socio-demographic, clinical and behavioural
haracteristics in relation to vaccine uptake within a publically-
unded HPV vaccination catch-up program for young adult women
n the community. In the study group, we found vaccine uptake
o be associated with being born in Australia, being single, being
ulliparous, living in higher socioeconomic status areas and living
n outer regional/remote/very remote areas. In the study popu-
ation, women who reported receiving the vaccine also reported
ewer sexual partners. However, we found an association between
accine uptake and history of other STIs, and we  also found an
ssociation with use of hormonal contraceptives, which is a doc-
mented co-factor in the development of invasive cervical cancer
7].
Our ﬁndings are in broad agreement with those of a prior Aus-
ralian study involving women aged 18–26 years in 2007 who
ere recruited as part of a mobile phone-based survey, which
ound that women reporting being vaccinated with ≥1 doses in
he catch-up phase were more likely to be born in Australia and
o be unmarried [1]. Our ﬁndings are also consistent with another
nalysis of National HPV Register data from the state of Victoria
or the cohort who were 18–26 years old in 2007, which demon-
trated a statistically signiﬁcantly lower 3-dose HPV vaccination
overage in the most disadvantaged areas compared to the least
isadvantaged areas (33.4% vs. 38.0%: p < 0.001) (although it should
e noted that this socioeconomic gradient was less pronounced
han that observed for cervical screening) [8]. This is an important
ssue because Australian women from lower socioeconomic status
reas are less likely to attend cervical screening [8,9] and are thus
t higher lifetime risk of developing cervical cancer.
Our ﬁndings that vaccination initiation was associated with liv-
ng in a higher socioeconomic status area appear broadly consistent
ith international studies for adult women offered HPV vaccina-
ion. High neighbourhood income was positively associated with
accination initiation in women aged 18–26 years in a US studyristics (shown in Table 2), and clinical and behavioural characteristics (shown in
conducted within a Managed Care Organization [10], and in other
US studies in young adult women, HPV vaccination initiation and/or
completion has also been associated with health insurance status
[11–16]. It should be noted that the relationship between socioeco-
nomic status and HPV vaccination may  differ between young adult
women and adolescent groups and may  also different between
populations. A recent systematic review of the international litera-
ture on inequalities in HPV vaccination in females aged 18 years or
younger identiﬁed strong evidence of heterogeneity in analyses of
area-level deprivation and HPV vaccination initiation - some, but
not all primary studies in this age group found that those living
in the most deprived areas were less likely to initiate HPV vacci-
nation than those living in the least deprived areas [17]. In general
terms, an association between area-level SES and uptake of the HPV
vaccine may  also indicate underlying factors such as beliefs and cul-
tural sensitivities which may  have inﬂuenced the decision to accept
vaccination [18].
In the current study, we found that vaccinated women were
more likely to report fewer sexual partners, however, adult women
who chose to be vaccinated in the catch-up phase also reported
certain other characteristics that potentially place them at an
increased risk of HPV exposure prior to vaccination (i.e. prior STI
exposure which may  act as a marker of higher risk of past HPV
exposure) or of progression of cervical HPV infection (i.e. use
of hormonal contraceptives). A recent study conducted on older
adolescents (16–17 year old girls) in the Netherlands found that
vaccinated and unvaccinated girls were comparable with respect
to most sexual risk behaviours (a slightly higher percentage of vac-
cinated girls were sexually active, but this group had fewer total
lifetime numbers of sexual partners) and no difference was found
for history of STIs in the sexually active group [19]. There have
been differing results from other international studies that have
assessed HPV vaccination in relation to sexual behaviour; some
studies in young adult women have found a positive association
between vaccination initiation or completion and a history of STIs
[10–12,15] or increasing number of sexual partners [13,20], while
other studies reported no association with these characteristics
[14,21]. Other studies in young adult women  have also found an
association between vaccination status and being single, unmarried
or never married (with the exact measure being study dependent)
[12,14,15,22].
The relationship identiﬁed in the current study between HPV
vaccine uptake and use of hormonal contraception, has not been
previously documented in the Australian National HPV Vaccination
Program and has only been investigated in a few other international
studies of young adult women  [10,11,21,23]. Hormonal contra-
ception use may  act as a proxy for accessing health services on a
regular basis, thus possibly increasing the likelihood of vaccination
in the catch-up phase, and/or it may  indicate increased awareness
of women’s health issues [24].
Our study is subject to some limitations. First, study participants
were recruited from a population of women attending cervical
screening and therefore ﬁndings and observed vaccination rates
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Table  3
Clinical and behavioural characteristics by self-reported HPV vaccination status, based on ≥1 doses, in women aged 20–29 years at study recruitment (2008–2009), in NSW,
Australia.
Characteristic Unvaccinated
n = 259 (23%)
Vaccinated
n = 880 (77%)
Unadjusted OR
(95%CI)
Adjusted OR
(95%CI)
Overall p-value
and p-trend
Number of pap smears#
None 51 (20%) 199 (80%) Ref. Ref.
One 89 (24%) 281 (76%) 0.81
(0.55–1.19)
0.75 (0.47–1.2) 0.70
Two  52 (22%) 185 (78%) 0.91
(0.59–1.41)
0.83 (0.49–1.4) 0.78
Three or more 67 (24%) 215 (76%) 0.82
(0.54–1.24)
0.82
(0.47–1.45)
Number of high grade lesions#,♣
None 238 (23%) 779 (77%) Ref. Ref.
One 7 (19%) 29 (81%) 1.27
(0.55–2.93)
0.93 (0.35–2.5) 0.42
Two  or more 14 (16%) 72 (84%) 1.57
(0.87–2.84)
1.59
(0.78–3.22)
0.23
Number of low grade lesions#,♣
None 222 (24%) 698 (76%) Ref. Ref.
One 21 (15%) 117 (85%) 1.77
(1.09–2.89)
1.46
(0.83–2.56)
0.33
Two or more 16 (20%) 65 (80%) 1.29
(0.73–2.28)
1.43
(0.69–2.95)
0.18
Number of high and low grade lesions#
None 212 (24%) 656 (76%) Ref. Ref.
One 19 (17%) 93 (83%) 1.58
(0.94–2.65)
1.28 (0.71–2.3) 0.13
Two  or more 28 (18%) 131 (82%) 1.51
(0.98–2.34)
1.78
(1.00–3.16)
0.05
Had other STI∼
No 224 (24%) 715 (76%) Ref. Ref. 0.03
Yes  35 (18%) 165 (83%) 1.48
(1.00–2.19)
1.66
(1.05–2.63)
n/a
Family history of cervical cancer or precancer
No family history 178 (24%) 579 (76%) Ref. Ref.
Mother and/or sister 29 (17%) 141 (83%) 1.49
(0.97–2.31)
1.82
(1.10–3.02)
0.07
Distant family member only 23 (25%) 69 (75%) 0.92
(0.56–1.52)
1.07 (0.60–1.9) n/a
Not  aware of any cervical cancer 29 (24%) 91 (76%) 0.96
(0.61–1.51)
0.77
(0.46–1.31)
Number of sexual partners ever
1 52 (25%) 156 (75%) Ref. Ref.
2–4  61 (20%) 248 (80%) 1.36
(0.89–2.06)
0.91
(0.55–1.51)
0.11
5–9 68 (24%) 221 (76%) 1.08
(0.72–1.64)
0.65
(0.39–1.09)
0.02*
10+ 57 (25%) 167 (75%) 0.98
(0.63–1.51)
0.54
(0.31–0.96)
Prefer not to answer 21 (19%) 88 (81%) 1.40
(0.79–2.47)
0.97
(0.48–1.95)
How often drink alcohol
Never/non-drinker 37 (42%) 51 (58%) Ref. Ref.
Ex-drinker 19 (58%) 14 (42%) 0.53
(0.24–1.20)
0.51 (0.20–1.3) <0.01
Less  than once a month 46 (20%) 184 (80%) 2.90
(1.70–4.94)
2.43
(1.31–4.49)
n/a
A  few days a month 116 (19%) 484 (81%) 3.03
(1.89–4.84)
1.66
(0.93–2.95)
More than 8 days a month 41 (22%) 147 (78%) 2.60
(1.51–4.49)
1.66
(0.85–3.25)
Smoking status
Never smoked 162 (21%) 599 (79%) Ref. Ref.
Ex-smoker 44 (28%) 116 (73%) 0.71
(0.48–1.05)
0.82 (0.51–1.3) 0.43
Occasional smoker 21 (20%) 83 (80%) 1.07
(0.64–1.78)
0.86
(0.48–1.54)
n/a
Regular smoker 32 (28%) 82 (72%) 0.69
(0.44–1.08)
0.65
(0.38–1.11)
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Table  3 (Continued)
Characteristic Unvaccinated
n = 259 (23%)
Vaccinated
n = 880 (77%)
Unadjusted OR
(95%CI)
Adjusted OR
(95%CI)
Overall p-value
and p-trend
Use of hormonal contraceptives
Current@ 129 (18%) 608 (82%) Ref. Ref.
Past 112 (32%) 239 (68%) 0.45
(0.34–0.61)
0.58
(0.41–0.81)
<0.01
Never used 18 (35%) 33 (65%) 0.39
(0.21–0.71)
0.54
(0.27–1.10)
n/a
 Adjusted for time vaccine was available to woman and socio-demographic (shown in Table 2), and clinical and behavioural characteristics (shown in Table 3).
# On or before reported year of vaccination in vaccinated subjects or reference test year in unvaccinated subjects.
♣ Fitted in separate model which excluded “number of high grade and low grade lesions” due to collinearity.
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* Trend statistic calculated by excluding subjects who preferred not to answer.
@ Includes pill, mini pill, implants, injections or intrauterine devices with hormon
re not representative of all young adult women at the time of
he delivery of catch-up vaccination in Australia. It is possible
hat some ‘opportunistic’ vaccination occurred in young women
resenting for cervical screening during the vaccination catch-up
hase (and/or vice-versa i.e. that opportunistic screening may  have
ccurred in those presenting for vaccination). Following the com-
letion of the catch-up phase, however, participation in cervical
creening appears to have declined in 20–29 year old women. A
ecent analysis using linked data from the National HPV Vaccina-
ion Register and the Victorian Cervical Cytology Register shows
hat participation in cervical screening was signiﬁcantly lower in
accinated women over the period 2009–2011 (i.e. a period sub-
equent to that over which recruitment to the current study was
onducted) [25].
A second limitation of the current study is that because recruit-
ent for the study ran concurrently to the catch-up program, it
as not possible to assess factors associated with completion of
he recommended 3-dose schedule. However, assessing uptake
f ≥1 doses of the HPV vaccine is consistent with other stud-
es which have investigated vaccine initiation, and we adjusted
or the time eligible for catch-up vaccination in the analysis. A
hird limitation of our study is that we used self-reported vacci-
ation uptake, and in our study group of women attending cervical
creening who had a normal cervical cytology result, we had a high
eported uptake of vaccination overall; but it is notable that the
eported uptake of 77% for ≥1 doses in the current study group is
roadly consistent with that of the self-reported 3-dose coverage
ate of ∼71% in a prior study of 18–24 year old women present-
ng for cervical screening in 2010–2011 (i.e. in a slightly younger
irth cohort) [26]. Furthermore, a prior Australian analysis of 629
elf-reported HPV vaccination doses has also shown that ∼86% of
elf-reports agreed with register/provider records [1] and a ∼90%
oncordance between self-reported and registry-reported vacci-
ation status was found in a survey of women aged 18–25 years
ecruited in 2011–2013 [27].
Despite the above limitations, the current study has a number
f strengths including the availability of a wide range of demo-
raphic, clinical and lifestyle characteristics and recruitment from
 single source, the NSW Pap Test Register, which collects informa-
ion on almost all women who have a Pap test, with a low opt-out
ate of <1% [28]. Our ﬁndings are in broad agreement with those of
ther Australian studies for the outcomes assessed in those studies,
owever the current study provides a more detailed description
f the characteristics of the women who chose to be vaccinated
gainst HPV in the catch-up phase of the National HPV Vaccination
rogram.
Substantial indications of the effect of the National HPV Vac-
ination Program in Australia were predicted [29,30] and have
lready been observed in young cohorts offered vaccination; these
nclude a substantial decline in the prevalence of vaccine-included
PV types in women aged 18–24 years [26], a decline in theincidence of anogenital warts in females under 30 years of age [31]
and a decline in high grade cervical precancerous lesions in young
women [32]. Linked data analysis between vaccination and cervical
screening registers have also demonstrated substantial reductions
in high grade precancerous abnormalities in vaccinated women  in
Australia [33,34]. Although this substantial and rapid effect of the
catch-up vaccination program is very reassuring, the ﬁndings of
the current study reinforce the continuing need to assess vaccine
uptake in different groups in the HPV vaccine-eligible population
and to prioritise equitable delivery of vaccination.
Authors’ contributions
KC conceived the project and wrote the ﬁrst full draft together
with LSV. SE performed the statistical analysis for this evaluation,
prepared the tables and ﬁgures and participated in drafting the
manuscript. DO’C provided statistical input. JDB was responsible
for the conduct of the study, recruitment of participants and coor-
dinated the project. FS is the Principal Investigator for the Cervical
Health Study. All authors had full access to all of the data, and can
take responsibility for the integrity of the data and the accuracy
of the data analysis. All authors contributed to the writing of the
manuscript, approved the ﬁnal version to be published and are
in agreement with the analysis, results and interpretation of the
ﬁndings. KC is the guarantor.
Funding
The study was funded by the National Health and Medical
Research Council Australia (NHMRC Project Grant ID 387701) and
by Cancer Council NSW. The funding sources had no involvement
in the study design, analysis, interpretation of results, writing of
the manuscript or the decision to submit for publication.
Conﬂict of interest statement
KC, DO’C, EB and FS have received grants from the National
Health and Medical Research Council. KC is co-PI of an investigator-
initiated trial of HPV-based cervical screening in Australia which is
conducted and funded by the Victorian Cytology Service and which
has received a funding contribution from Roche Molecular Systems
and Ventana Inc., USA; JBD is the project coordinator for the same
trial. LSV and SE have nothing to disclose.
AcknowledgementsWe thank the NSW Cervical Screening Program, NSW Pap
Test Register Staff, Cancer Institute NSW and NSW Health for
assistance in recruitment for this study; and we thank Aye Moa
and Barbara Ling for their contribution to study recruitment and
2 cine 33
c
m
P
b
S
f
b
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
of  cervical abnormalities: case-control study nested within a population based394 K. Canfell et al. / Vac
oordination. We  also thank Professor Ian Frazer for his involve-
ent in the larger study described here. We  are also thankful to
rofessors Neville Hacker, Chris Dalrymple, Jonathan Carter, Bar-
ara Rose, Yvonne Cossart (deceased), Dr Yequin Zhuo, and David
hanzer who assisted us at various stages of the study. We grate-
ully acknowledge the helpful review of the ﬁnal draft of the paper
y Ms.  Megan Smith.
eferences
[1] Brotherton JM,  Liu B, Donovan B, Kaldor JM,  Saville M.  Human papillomavirus
(HPV) vaccination coverage in young Australian women  is higher than pre-
viously estimated: independent estimates from a nationally representative
mobile phone survey. Vaccine 2014;32:592–7.
[2] Weisberg E, Bateson D, McCaffery K, Skinner SR. HPV vaccination catch
up  program—utilisation by young Australian women. Aust Fam Phys
2009;38:72–6.
[3] Cooper Robbins SC, Bernard D, McCaffery K, Skinner SR. Is cancer contagious?:¨
Australian adolescent girls and their parents: making the most of limited infor-
mation about HPV and HPV vaccination. Vaccine 2010;28:3398–408.
[4] Future II Study Group. Quadrivalent vaccine against human papillomavirus to
prevent high-grade cervical lesions. N Engl J Med  2007;356:1915–27.
[5] Census of Population and Housing: Socio-Economic Indexes for Areas
(SEIFA), Australia, 2011 (cat. no. 2033.0.55.001). Australian Bureau of Statis-
tics  2011. 〈http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa〉.
(accessed November 2013).
[6] Australian Statistical Geography Standard (ASGS) Volume 5 – Remoteness
Areas, July 2011 (cat. no. 1270.0.55.005). 〈http://www.abs.gov.au/websitedbs/
d3310114.nsf/home/remoteness+structure〉. (accessed November 2013).
[7]  International Collaboration of Epidemiological Studies of Cervical Cancer,
Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, et al. Cervical
cancer and hormonal contraceptives: collaborative reanalysis of individual data
for 16,573 women with cervical cancer and 35,509 women without cervical
cancer from 24 epidemiological studies. Lancet 2007;370:1609–21.
[8] Barbaro B, Brotherton JM,  Gertig DM.  Human papillomavirus vaccination
and  cervical cancer screening by socioeconomic status. Victoria Med  J Aust
2012;196:445.
[9] AIHW. Australian Institute of Health and Welfare. Cervical screening in
Australia 2007–2008. In: Cat. No. CAN 50. 2010. Australian Institute of Health
and  Welfare; 2010. Cancer series number 47, (Ref type: report).
10] Chao C, Velicer C, Slezak JM,  Jacobsen SJ. Correlates for human papillomavirus
vaccination of adolescent girls and young women in a managed care organiza-
tion. Am J Epidemiol 2010;171:357–67.
11] Wei  F, Moore PC, Green AL. Geographic variability in human papillomavirus
vaccination among U.S. young women. Am J Prev Med  2013;44:154–7.
12] Williams WW,  Lu PJ, Saraiya M,  Yankey D, Dorell C, Rodriguez JL, et al. Factors
associated with human papillomavirus vaccination among young adult women
in  the United States. Vaccine 2013;31:2937–46.
13] Tiro JA, Tsui J, Bauer HM,  Yamada E, Kobrin S, Breen N. Human papillomavirus
vaccine use among adolescent girls and young adult women: an analysis
of  the 2007 California Health Interview Survey. J Womens Health (Larchmt)
2012;21:656–65.
14] Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and
sexual behavior among adolescent and young women. Am J Prev Med
2012;42:44–52.
15] Anhang Price R, Tiro JA, Saraiya M,  Meissner H, Breen N. Use of human papillo-
mavirus vaccines among young adult women  in the United States: an analysis
of  the 2008 National Health Interview Survey. Cancer 2008;117:5560–8.
[ (2015) 2387–2394
16] Dempsey A, Cohn L, Dalton V, Rufﬁn M.  Worsening disparities in HPV vaccine
utilization among 19–26 year old women. Vaccine 2011;29(3):528–34.
17] Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M.  Inequalities
in  the uptake of human papillomavirus vaccination: a systematic review and
meta-analysis. Int J Epidemiol 2013;42:896–908.
18] Larson HJ. The uptake of human papillomavirus vaccination: the power of
belief. Int J Epidemiol 2013;42:908–10 (Commentary).
19] Mollers M, Lubbers K, Spoelstra SK, Weijmar-Schultz WC,  Daemen T, Westra TA,
et  al. Equity in human papilloma virus vaccination uptake?: sexual behaviour,
knowledge and demographics in a cross-sectional study in (un)vaccinated girls
in  the Netherlands. BMC  Public Health 2014;14:288.
20] Bernat DH, Gerend MA,  Chevallier K, Zimmerman MA,  Bauermeister JA. Char-
acteristics associated with initiation of the human papillomavirus vaccine
among a national sample of male and female young adults. J Adolesc Health
2013;53:630–6.
21] Chao C, Velicer C, Slezak JM,  Jacobsen SJ. Correlates for completion of 3-dose
regimen of HPV vaccine in female members of a managed care organization.
Mayo Clin Proc 2009;84:864–70.
22] Schmidt S, Parsons HM.  Vaccination interest and trends in human papillo-
mavirus vaccine uptake in young adult women aged 18 to 26 years in the United
States: an analysis using the 2008–2012 National Health Interview Survey. Am
J  Public Health 2014;104:946–53.
23] Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA. Adherence to the
HPV vaccine dosing intervals and factors associated with completion of 3 doses.
Pediatrics 2011;127:77–84.
24] Mills LA, Vanderpool RC, Crosby RA. Sexually related behaviors as predictors
of  HPV vaccination among young rural women. J Womens Health (Larchmt)
2011;20:1909–15.
25] Budd AC, Brotherton JM,  Gertig DM,  Chau T, Drennan KT, Saville M.  Cervical
screening rates for women vaccinated against human papillomavirus. Med  J
Aust 2014;201(5):279–82.
26] Tabrizi SN, Brotherton JM,  Kaldor JM,  Skinner SR, Cummins E, Liu B, et al. Fall in
human papillomavirus prevalence following a national vaccination program. J
Infect Dis 2012;206:1645–51.
27] Osborne SL, Tabrizi SN, Brotherton JM,  Cornall AM, Wark JD, Wrede CD,  et al.,
VACCINE Study group. Assessing genital human papillomavirus genopreva-
lence in young Australian women following the introduction of a national
vaccination program. Vaccine 2015;33:201–8.
28] Cancer Institute NSW. Cervical Cancer Screening in New South Wales. Annual
Statistical Report 2010–2011. May  2014. 〈http://www.cancerinstitute.org.au/
media/363045/Cervical-Screening-Annual-Statistical-Report-2010-2011.PDF〉.
[accessed February 2015].
29] Smith MA,  Canfell K, Brotherton JM,  Lew JB, Barnabas RV. The predicted impact
of vaccination on human papillomavirus infections in Australia. Int J Cancer
2008;123:1854–63.
30] Smith MA,  Canfell K. Testing previous model predictions against new data
on  human papillomavirus vaccination program outcomes. BMC  Res Notes
2014;7:109.
31] Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in
young Australians ﬁve years into national human papillomavirus vaccination
programme: national surveillance data. BMJ  2013;346:f2032.
32] Australian Institute of Health and Welfare. Cervical screening in Australia
2010–2011. Canberra: AIHW; 2013. Cancer series 76. Cat. no. CAN 72.
33] Crowe E, Pandeya N, Brotherton JM,  Dobson AJ, Kisely S, Lambert SB, et al.
Effectiveness of quadrivalent human papillomavirus vaccine for the preventionscreening programme in Australia. BMJ  2014;348:g1458.
34] Gertig DM,  Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.  Impact
of a population-based HPV vaccination program on cervical abnormalities: a
data linkage study. BMC Med  2013:11.
